

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A stable immunogenic product for inducing antibodies raised against a TNF α protein in a subject, ~~characterized in that it comprises~~ the immunogenic product comprising protein immunogenic heterocomplexes comprising ~~consisting of associations between (i) TNF α protein molecules and (ii) associated with~~ KLH carrier protein molecules, and in that wherein more than 1% and less than 40% of the ~~antigenic proteins (i) are~~ TNF α protein molecules are directly covalently linked to the KLH carrier protein molecules, and more than 60% of the TNF α protein molecules are non-covalently associated with the KLH carrier protein ~~(ii), and wherein the covalent bonds between one or more TNF α proteins and the KLH protein molecule are made through a bifunctional bond chemical agent consisting of glutaraldehyde.~~

2. (currently amended) An immunogenic product according to claim 1, ~~characterized in that~~ wherein each immunogenic heterocomplex comprises (i) a plurality of TNF α proteins covalently linked to (ii) a KLH carrier protein molecule.

3. (currently amended) An immunogenic product according to claim 2, ~~characterized in that for each immunogenic heterocomplex,~~ wherein the plurality of TNF α proteins ~~(i)~~ is ~~made up of~~ a plurality of specimens of a single TNF α protein.

4-20. (cancelled)

21. (previously presented) A composition comprising an immunogenic product according to claim 1.

22. (previously presented) A pharmaceutical composition comprising an immunogenic product according to claim 1 in association with one or more physiologically compatible excipients.

23. (previously presented) An immunogenic composition comprising an immunogenic product according to claim 1 in association with one or more physiologically compatible excipients.

24. (previously presented) A vaccine composition comprising an immunogenic product according to claim 1 in association with one or more physiologically compatible excipients.

25. (currently amended) An immunogenic composition according to claim 23, ~~characterized in that it comprises the~~ comprising a CpG immunity adjuvant.

26. (withdrawn - currently amended) A method for preparing an immunogenic product according to claim 1, ~~characterized in that it comprises the following steps of~~ comprising:

a) incubating ~~the antigenic~~ TNF α proteins ~~(i)~~ and ~~the~~ KLH carrier molecule ~~(ii)~~ in a molar ratio ~~(i):(ii)~~ TNF α :KLH ranging from 10:1 to 50:1 in the presence of a chemical binding agent to produce immunogenic heterocomplexes, and[[;]]

b) collecting the immunogenic product comprising immunogenic heterocomplexes ~~being~~ prepared in step a).

27. (withdrawn - currently amended) A method according to claim 26, ~~characterized in that~~ wherein the chemical binding agent is glutaraldehyde.

28. (withdrawn - currently amended) A method according to claim 26, ~~characterized in that~~ wherein step a) is followed by a stabilizing step of the immunogenic heterocomplexes by ~~the~~ formaldehyde, prior to ~~the~~ step b) of collecting the immunogenic product.

29. (cancelled)